Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development at Edwards Lifesciences (EW), sold 4,676 shares in the open market on April 2, 2026 at $80.59 per share, for total proceeds of about $376,850. Open-market sales are closely watched because they reflect a discretionary decision to reduce a personal stake at a known market price. Bobo’s role is relevant because strategy and corporate development leaders are typically involved in long-term planning, partnerships, and potential acquisitions, giving them a broad view of the company’s direction (within the limits of trading rules and blackout periods). While a single mid-six-figure sale is not necessarily unusual for a senior executive, it can matter to investors as a data point on insider sentiment and positioning. This transaction also follows Bobo’s earlier sale on March 2, 2026, when he sold 11,340 shares for roughly $974,430, indicating a recent pattern of trimming his holdings rather than a one-off sale. Over the last 30 days, the only reported insider trade provided is Bobo’s April 2 sale, so the near-term signal is concentrated in one executive’s activity rather than broad-based selling across the leadership team.